Child/Adolescent Anxiety Multimodal Study (CAMS): rationale, design, and methods

Scott N Compton, John T Walkup, Anne Marie Albano, John C Piacentini, Boris Birmaher, Joel T Sherrill, Golda S Ginsburg, Moira A Rynn, James T McCracken, Bruce D Waslick, Satish Iyengar, Phillip C Kendall, John S March, Scott N Compton, John T Walkup, Anne Marie Albano, John C Piacentini, Boris Birmaher, Joel T Sherrill, Golda S Ginsburg, Moira A Rynn, James T McCracken, Bruce D Waslick, Satish Iyengar, Phillip C Kendall, John S March

Abstract

Objective: To present the design, methods, and rationale of the Child/Adolescent Anxiety Multimodal Study (CAMS), a recently completed federally-funded, multi-site, randomized placebo-controlled trial that examined the relative efficacy of cognitive-behavior therapy (CBT), sertraline (SRT), and their combination (COMB) against pill placebo (PBO) for the treatment of separation anxiety disorder (SAD), generalized anxiety disorder (GAD) and social phobia (SoP) in children and adolescents.

Methods: Following a brief review of the acute outcomes of the CAMS trial, as well as the psychosocial and pharmacologic treatment literature for pediatric anxiety disorders, the design and methods of the CAMS trial are described.

Results: CAMS was a six-year, six-site, randomized controlled trial. Four hundred eighty-eight (N = 488) children and adolescents (ages 7-17 years) with DSM-IV-TR diagnoses of SAD, GAD, or SoP were randomly assigned to one of four treatment conditions: CBT, SRT, COMB, or PBO. Assessments of anxiety symptoms, safety, and functional outcomes, as well as putative mediators and moderators of treatment response were completed in a multi-measure, multi-informant fashion. Manual-based therapies, trained clinicians and independent evaluators were used to ensure treatment and assessment fidelity. A multi-layered administrative structure with representation from all sites facilitated cross-site coordination of the entire trial, study protocols and quality assurance.

Conclusions: CAMS offers a model for clinical trials methods applicable to psychosocial and psychopharmacological comparative treatment trials by using state-of-the-art methods and rigorous cross-site quality controls. CAMS also provided a large-scale examination of the relative and combined efficacy and safety of the best evidenced-based psychosocial (CBT) and pharmacologic (SSRI) treatments to date for the most commonly occurring pediatric anxiety disorders. Primary and secondary results of CAMS will hold important implications for informing practice-relevant decisions regarding the initial treatment of youth with anxiety disorders.

Trial registration: ClinicalTrials.gov NCT00052078.

Figures

Figure 1
Figure 1
Child/Adolescent Anxiety Multimodal Study (CAMS) Experimental Design.
Figure 2
Figure 2
Child/Adolescent Multimodal Study (CAMS) Organizational Structure and Performance Sites.

References

    1. Costello EJ, Egger HL, Angold A. The Developmental Epidemiology of Anxiety Disorders: Phenomenology, Prevalence, and Comorbidity. Child and Adolescent Psychiatric Clinics of North America. 2005;14:631–648. doi: 10.1016/j.chc.2005.06.003.
    1. Ezpeleta L, Keeler G, Erkanli A, Costello EJ, Angold A. Epidemiology of psychiatric disability in childhood and adolescence. Journal of Child Psychology & Psychiatry & Allied Disciplines. 2001;42:901–914.
    1. Kessler RC, Berglund P, Demler O, Jin R, Walters EE. Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey Replication. Archives of General Psychiatry. 2005;62:593–602. doi: 10.1001/archpsyc.62.6.593.
    1. Wittchen H-U, Stein M, Kessler R. Social fears and social phobia in a community sample of adolescents and young adults: Prevalence, risk factors and co-morbidity. Psychological Medicine. 1999;29:309–323. doi: 10.1017/S0033291798008174.
    1. Albano AM, Chorpita BF, Barlow DH. Child psychopathology. 2. New York, NY: Guilford Press; 2003. Childhood anxiety disorders; pp. 279–329.
    1. Kendall PC, Brady EU. In: Anxiety and depression in adults and children Banff international behavioral science series. Craig KD, Dobson KS, editor. Thousand Oaks, CA: Sage Publications, Inc; 1995. Comorbidity in the anxiety disorders of childhood: Implications for validity and clinical significance; pp. 3–36.
    1. Ialongo N, Edelsohn G, Werthamer-Larsson L, Crockett L, Kellams S. The significance of self-reported anxious symptoms in first-grade children. Journal of Abnormal Child Psychology. 1994;22:441–455. doi: 10.1007/BF02168084.
    1. Lapine J-P. The epidemiology of anxiety disorders: Prevalence and societal costs. Journal of Clinical Psychiatry. 2002;63:4–8.
    1. Smit F, Cuijpers P, Oostenbrink J, Batelaan N, de Graaf R, Beekman A. Costs of Nine Common Mental Disorders: Implications for Curative and Preventive Psychiatry. Journal of Mental Health Policy and Economics. 2006;9:193–200.
    1. James A, Soler A, Weatherall R. Cognitive behavioural therapy for anxiety disorders in children and adolescents. Cochrane Database of Systematic Reviews. 2005. p. CD004690.
    1. Dieleman GC, Ferdinand RF. Pharmacotherapy for social phobia, generalised anxiety disorder and separation anxiety disorder in children and adolescents: an overview. Tijdschrift voor Psychiatrie. 2008;50:43–53.
    1. Silverman WK, Pina AA, Viswesvaran C. Evidence-based psychosocial treatments for phobic and anxiety disorders in children and adolescents. Journal of Clinical Child & Adolescent Psychology. 2008;37:105–130.
    1. Compton SN, March JS, Brent D, Albano AM, Weersing VR, Curry J. Cognitive-Behavioral Psychotherapy for Anxiety and Depressive Disorders in Children and Adolescents: An Evidence-Based Medicine Review. Journal of the American Academy of Child & Adolescent Psychiatry. 2004;43:930–959.
    1. Beidel D, Albano A, Cooley-Quille M, Hibbs E, March J, Masia C, Morris T, Rabian B, Warren S. Conference on treating anxiety disorders in youth: current problems and future solutions. Anxiety Disorders Association of America; Bethesda, MD. 1999.
    1. Walkup JT, Albano AM, Piacentini J, Birmaher B, Compton SN, Sherrill JT, Ginsburg GS, Rynn MA, McCracken J, Waslick B, Iyengar S, March JS, Kendall PC. Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. New England Journal of Medicine. 2008;359:2753–2766. doi: 10.1056/NEJMoa0804633.
    1. Guy W. The ECDEU Assessment Manual for Psychopharmacology-Revised. Volume DHEW Publ No ADM 76-338. Rockville, MD: U.S. Department of Health, Education, and Welfare Public Health Service, Alcohol, Drug Abuse, Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research; 1976. The clinical global impression scale; pp. 218–222.
    1. RUPP Anxiety Study Group. The Pediatric Anxiety Rating Scale (PARS): development and psychometric properties. Journal of the American Academy of Child & Adolescent Psychiatry. 2002;41:1061–1069.
    1. Kendall PC. Treating anxiety disorders in children: Results of a randomized clinical trial. Journal of Consulting & Clinical Psychology. 1994;62:100–110.
    1. Kendall PC, Flannery-Schroeder E, Panichelli-Mindel SM, Southam-Gerow M, Henin A, Warman M. Therapy for youths with anxiety disorders: A second randomized clinical trial. Journal of Consulting & Clinical Psychology. 1997;65:366–380.
    1. Kendall PC, Hudson JL, Gosch E, Flannery-Schroeder E, Suveg C. Cognitive-behavioral therapy for anxiety disordered youth: a randomized clinical trial evaluating child and family modalities. Journal of Consulting & Clinical Psychology. 2008;76:282–297. doi: 10.1037/0022-006X.76.2.282.
    1. Birmaher B, Axelson DA, Monk K, Kalas C, Clark DB, Ehmann M, Bridge J, Heo J, Brent DA. Fluoxetine for the treatment of childhood anxiety disorders. Journal of the American Academy of Child & Adolescent Psychiatry. 2003;42:415–423.
    1. Compton SN, Grant PJ, Chrisman AK, Gammon PJ, Brown VL, March JS. Sertraline in children and adolescents with social anxiety disorder: An open trial. Journal of the American Academy of Child & Adolescent Psychiatry. 2001;40:564–571.
    1. Pine DS, Walkup JT, Labellarte MJ, Riddle MA, Greenhill L, Klein R, Davies M, Sweeney M, Abikoff H, Hack S, Klee B, McCracken J, Bergman L, Piacentini J, March J, Compton S, Robinson J, O'Hara T, Baker S, Vitiello B, Ritz L, Roper M. Fluvoxamine for the treatment of anxiety disorders in children and adolescents. New England Journal of Medicine. 2001;344:1279–1285. doi: 10.1056/NEJM200104263441703.
    1. Rynn MA, Siqueland L, Rickels K. Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder. American Journal of Psychiatry. 2001;158:2008–2014. doi: 10.1176/appi.ajp.158.12.2008.
    1. Compton SN, Burns BJ, Egger HL, Robertson E. Review of the evidence base for treatment of childhood psychopathology: Internalizing disorders. Journal of Consulting & Clinical Psychology. 2002;70:1240–1266.
    1. Beidel DC, Turner SM, Sallee FR, Ammerman RT, Crosby LA, Pathak S. SET-C versus fluoxetine in the treatment of childhood social phobia. Journal of the American Academy of Child & Adolescent Psychiatry. 2007;46:1622–1632.
    1. Pediatric OCD Treatment Study (POTS) Team. Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial. Journal of the American Medical Association. 2004;292:1969–1976. doi: 10.1001/jama.292.16.1969.
    1. Kendall PC, Gosch E, Furr JM, Sood E. Flexibility within fidelity. Journal of the American Academy of Child & Adolescent Psychiatry. 2008;47:987–993.
    1. Kendall PC, Safford S, Flannery-Schroeder E, Webb A. Child Anxiety Treatment: Outcomes in Adolescence and Impact on Substance Use and Depression at 7.4-Year Follow-Up. Journal of Consulting & Clinical Psychology. 2004;72:276–287.
    1. Silverman WK, Pina AA, Viswesvaran C. Evidence-based psychosocial treatments for phobic and anxiety disorders in children and adolescents. Journal of Clinical Child and Adolescent Psychology. 2008;37:105–130. doi: 10.1080/15374410701817907.
    1. Klein DF. Control groups in pharmacotherapy and psychotherapy evaluations. Treatment. 1997;1 doi: 10.1037/1522-3736.1.1.11a.
    1. Birmaher B, Waterman GS, Ryan N, Cully M. Fluoxetine for childhood anxiety disorders. Journal of the American Academy of Child & Adolescent Psychiatry. 1994;33:993–999.
    1. Black B, Uhde TW. Treatment of elective mutism with fluoxetine: A double-blind, placebo-controlled study. Journal of the American Academy of Child & Adolescent Psychiatry. 1994;33:1000–1006.
    1. Mancini C, Van Ameringen M, Oakman JM, Farvolden P. Serotonergic agents in the treatment of social phobia in children and adolescents: a case series. Depression & Anxiety. 1999;10:33–39.
    1. March JS, Biederman J, Wolkow R, Safferman A, Mardekian J, Cook EH, Cutler NR, Dominguez R, Ferguson J, Muller B, Riesenberg R, Rosenthal M, Sallee FR, Wagner KD. Sertraline in children and adolescents with obsessive-compulsive disorder: A multicenter randomized controlled trial. Journal of the American Medical Association. 1998;280:1752–1756. doi: 10.1001/jama.280.20.1752.
    1. March JS, Entusah AR, Rynn M, Albano AM, Tourian KA. A randomized controlled trial of venlafaxine ER versus placebo in pediatric social anxiety disorder. Biological Psychiatry. 2007;62:1149–1154. doi: 10.1016/j.biopsych.2007.02.025.
    1. Riddle MA, Reeve EA, Yaryura-Tobias JA, Yang HM, Claghorn JL, Gaffney G, Greist JH, Holland D, McConville BJ, Pigott T, Walkup JT. Fluvoxamine for children and adolescents with Obsessive-Compulsive Disorder: A randomized, controlled, multicenter trial. Journal of the American Academy of Child & Adolescent Psychiatry. 2001;40:222–229.
    1. Suicidality in Children and Adolescents Being Treated With Antidepressant Medications.
    1. The MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Archives of General Psychiatry. 1999;56:1073–1086. doi: 10.1001/archpsyc.56.12.1073.
    1. TADS Study Team. Fluoxetine, Cognitive-Behavioral Therapy, and Their Combination for Adolescents With Depression: Treatment for Adolescents With Depression Study (TADS) Randomized Controlled Trial. Journal of the American Medical Association. 2004;292:807–820. doi: 10.1001/jama.292.7.807.
    1. Brent D, Emslie G, Clarke G, Wagner KD, Asarnow JR, Keller M, Vitiello B, Ritz L, Iyengar S, Abebe K, Birmaher B, Ryan N, Kennard B, Hughes C, DeBar L, McCracken J, Strober M, Suddath R, Spirito A, Leonard H, Melhem N, Porta G, Onorato M, Zelazny J. Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial. Journal of the American Medical Association. 2008;299:901–913. doi: 10.1001/jama.299.8.901.
    1. Jureidini J, Tonkin A, Mansfield PR. TADS study raises concerns. British Medical Journal. 2004;329:133-d–1344-d. doi: 10.1136/bmj.329.7478.1343-d.
    1. Kendall PC, Compton SN, Walkup JT, Birmaher B, Albano AM, Sherrill JT, Ginsburg GS, Rynn MA, McCracken J, Gosch E, Keeton CP, Bergman L, Sakolsky D, Suveg C, Iyengar S, March JS, Piacentini J. Clinical characteristics of anxiety disorded youth. Journal of Anxiety Disorders. under review.
    1. Kendall PC, Hudson JL, Gosch E, Flannery-Schroeder E, Suveg C. Cognitive-behavioral therapy for anxiety disordered youth: A randomized clinical trial evaluating child and family modalities. Journal of Consulting & Clinical Psychology. 2008;76:282–297. doi: 10.1037/0022-006X.76.2.282.
    1. Alvarez RA, Vasquez E, Mayorga CC, Feaster DJ, Mitrani VB. Increasing minority research participation through community organization outreach. Western Journal of Nursing Research. 2006;28:541–560. doi: 10.1177/0193945906287215. discussion 561-543.
    1. Kendall P. The C.A.T. Project Therapist Manual. Ardmore, PA: Workbook Publishing; 1990.
    1. Kendall PC, Choudhury M, Hudson J, Webb A. The C.A.T. project therapist manual. Ardmore, PA: Workbook Publishing; 2002.
    1. March JS. Authors of TADS study reply to letter raising concerns. British Medical Journal. 2005;330:730–731. doi: 10.1136/bmj.330.7493.730-b.
    1. Brent DA. The treatment of SSRI-resistant depression in adolescents (TORDIA): in search of the best next step. Depress Anxiety. 2009;26:871–874. doi: 10.1002/da.20617.
    1. March JS, Vitiello B. Benefits exceed risks of newer antidepressant medications in youth—maybe. Clinical Pharmacology & Therapeutics. 2009;86:355–357.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅